Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation

SANTA ANA, Calif.--()--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Litigation:

Important Notice from the United States District Court
for the Central District of California

This statement is intended to give you notice of a pending Class Action for alleged securities fraud against Puma Biotechnology, Inc. (PBYI). If you purchased or otherwise acquired securities of Puma Biotechnology, Inc. (PBYI) between July 22, 2014 and May 29, 2015, you may be a Class member.

At this time, Class members are not required to take any action to remain in the Class. If any benefits are eventually obtained for the Class as a result of this lawsuit, eligible Class members may be entitled to a payment.

Class members may choose to exclude themselves from the Class. If you exclude yourself, you will not be entitled to a payment if any benefits are eventually obtained for the Class. If you do not exclude yourself, you will be bound by any judgment in this litigation, whether favorable or unfavorable. To remain a Class member and eligible for a payment if any benefits are eventually obtained, you are not required to do anything at this time. Requests for exclusion forms are available at www.pumabiosecuritieslitigation.com or can be obtained by calling 866-880-1572. The deadline to exclude yourself is June 6, 2018.

For a full description of the litigation, including identification of the plaintiff, defendants, Class Counsel, and the allegations of securities fraud, as well as related Court documents, please visit:

www.pumabiosecuritieslitigation.com

Contacts

Robbins Geller Rudman & Dowd LLP
Ted Pintar, 619-231-1058

Recent Stories

RSS feed for Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP